Skip to the content Skip to the main menu
ShroomStocks.ca

Investing is a trip

  • Featured Content
  • Mushrooms
  • Psychedelics
  • Psilocybin
  • Microdosing
  • Media

Top Posts & Pages

  • We downloaded RLOVE, a dating app for psychonauts and "light warriors." Here's what happened
    We downloaded RLOVE, a dating app for psychonauts and "light warriors." Here's what happened
  • Braxia Scientific (BRAX.C) files Q4 and year-end financials, including big losses
    Braxia Scientific (BRAX.C) files Q4 and year-end financials, including big losses
  • Filament Health (FH.NEO) Receives Regulatory Approval, Positioned to Lead Natural Psychedelic Research and Manufacturing
    Filament Health (FH.NEO) Receives Regulatory Approval, Positioned to Lead Natural Psychedelic Research and Manufacturing
  • The City of Santa Cruz joins the shroom-boom
    The City of Santa Cruz joins the shroom-boom
  • Nutritional High International (EAT.C) expands their psychoactive research to include peyote
    Nutritional High International (EAT.C) expands their psychoactive research to include peyote

Recent Posts

  • Red Light (TRIP.C) enters definitive agreement for Mera Life Sciences acquisition
  • Braxia Scientific (BRAX.C) files Q4 and year-end financials, including big losses
  • Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering
  • Filament Health (FH.NEO) Receives Regulatory Approval, Positioned to Lead Natural Psychedelic Research and Manufacturing
  • MindMed (MND.Q) announces intravenous DMT Phase 1 study
  • Braxia Scientific (BRAX.C) CEO and Chief Medical Officer receive $918,000 grant to study ketamine assisted iCBT
  • Mind Cure (MCUR.C) launches second stage of ibogaine manufacturing
  • Psyched Wellness (PSYC.C) completes largest extraction of AME-1 to date and ships it to CRO in Asia
  • Cybin (CYBN.NE) receives conditional approval to list on the NYSE
  • Mydecine Innovations (MYCO.NE) files patent for MDMA-like compounds
  • Tryp Therapeutics (TRYP.C) announces plans for TRYP-8802 Phase 2a study on fibromyalgia
  • Military veterans and RCMP officers to have ketamine treatment from Braxia Scientific (BRAX.C) fully covered by Medavie Blue Cross
  • About

Investing is a trip

  • Home
  • Posts

Top Posts & Pages

  • We downloaded RLOVE, a dating app for psychonauts and "light warriors." Here's what happened
    We downloaded RLOVE, a dating app for psychonauts and "light warriors." Here's what happened
  • Braxia Scientific (BRAX.C) files Q4 and year-end financials, including big losses
    Braxia Scientific (BRAX.C) files Q4 and year-end financials, including big losses
  • Filament Health (FH.NEO) Receives Regulatory Approval, Positioned to Lead Natural Psychedelic Research and Manufacturing
    Filament Health (FH.NEO) Receives Regulatory Approval, Positioned to Lead Natural Psychedelic Research and Manufacturing
  • The City of Santa Cruz joins the shroom-boom
    The City of Santa Cruz joins the shroom-boom
  • Nutritional High International (EAT.C) expands their psychoactive research to include peyote
    Nutritional High International (EAT.C) expands their psychoactive research to include peyote

Recent Posts

  • Red Light (TRIP.C) enters definitive agreement for Mera Life Sciences acquisition
  • Braxia Scientific (BRAX.C) files Q4 and year-end financials, including big losses
  • Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering
  • Filament Health (FH.NEO) Receives Regulatory Approval, Positioned to Lead Natural Psychedelic Research and Manufacturing
  • MindMed (MND.Q) announces intravenous DMT Phase 1 study
  • Braxia Scientific (BRAX.C) CEO and Chief Medical Officer receive $918,000 grant to study ketamine assisted iCBT
  • Mind Cure (MCUR.C) launches second stage of ibogaine manufacturing
  • Psyched Wellness (PSYC.C) completes largest extraction of AME-1 to date and ships it to CRO in Asia
  • Cybin (CYBN.NE) receives conditional approval to list on the NYSE
  • Mydecine Innovations (MYCO.NE) files patent for MDMA-like compounds
  • Tryp Therapeutics (TRYP.C) announces plans for TRYP-8802 Phase 2a study on fibromyalgia
  • Military veterans and RCMP officers to have ketamine treatment from Braxia Scientific (BRAX.C) fully covered by Medavie Blue Cross
  • About

Red Light (TRIP.C) enters definitive agreement for Mera Life Sciences acquisition

  • Post date
    July 30, 2021
  • Posted by
    Piers Eaton
  • Posted in Biotech, Eaton, Greadines, Health Science, Mera Life Sciences, Mushrooms, Psychedelic Tourism, Psychedelics, Scribes, St Vincent, SVG
  • Comments
    0

Braxia Scientific (BRAX.C) files Q4 and year-end financials, including big losses

  • Post date
    July 30, 2021
  • Posted by
    Piers Eaton
  • Posted in Big Losses, Biotech, braxia, braxia scientific, Eaton, financial statements, Health Science, Psychedelics, Rebranding, Scribes
  • Comments
    0

Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering

  • Post date
    July 29, 2021
  • Posted by
    Piers Eaton
  • Posted in Biotech, CYB001, CYB003, CYB004, cybin, CYBN.NE, Eaton, Health Science, Mushrooms, NYSE, NYSE American, psilocybin, Psychedelics, Public Offering, Scribes
  • Comments
    0

Filament Health (FH.NEO) Receives Regulatory Approval, Positioned to Lead Natural Psychedelic Research and Manufacturing

  • Post date
    July 29, 2021
  • Posted by
    Kieran Robertson
  • Posted in FH.NE, FH.NEO, Filament Health, filament health clinical trials, Health Science, Mushrooms, natural psychedelics, psilocybin, Psychedelics, Robertson, Scribes
  • Comments
    0

MindMed (MND.Q) announces intravenous DMT Phase 1 study

  • Post date
    July 28, 2021
  • Posted by
    Piers Eaton
  • Posted in Biotech, Eaton, Health Science, Intravenous, MindMEd, mmed.ne, Phase 1 Study, Psychedelics, Scribes, Switzerland, UHB
  • Comments
    0

Nothing more to load.

Next Page →

Theme by Anders Norén